12:00 AM
 | 
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Aubagio teriflunomide: Phase III data

Top-line data from the double-blind, international Phase III TOPIC trial in 618 patients who had experienced their first neurological symptoms consistent with CIS showed that once-daily 7 and 14 mg doses of oral Aubagio each met the primary endpoint of reducing the risk of conversion to clinically definite MS over 2 years vs. placebo. Specifically, Aubagio led to placebo-adjusted reductions in the risk of conversion to...

Read the full 307 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >